On October 24, 2022 Celaid Therapeutics Inc. (Head office: Bunkyo-ku, Tokyo; President: Nobuyuki Arakawa) reported a third-party allotment of new shares with The University of Tokyo Edge Capital Partners Co., Ltd. as the lead investor, Tsukuba Institute of Research, Ltd. and SBI Regional Revitalization Support Corporation, and Techno Science Co (Press release, Celaid Therapeutics, OCT 24, 2022, View Source [SID1234649813]). The total amount of funds raised is approximately 500 million yen.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With this financing, Celaid will further accelerate the development of cell therapy products for blood cancers such as acute leukemia.